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An immunosensor capable of high sensitivity detection of beta-amyloid peptides, shown to be a reliable
biomarker for Alzheimer's disease, has been developed using screen printed graphene electrodes
(SPGEs) modified with ultra-thin layers of polymerised 1,5-diaminonaphthalene (pDAN).
Electropolymerization of 1,5-diaminonaphthalene (DAN) was performed to coat the graphene screen
printed electrodes in a continuous polymer layer with controlled thickness. The surface characteristics of
pristine graphene and polymer modified graphene electrodes were examined using Raman and X-ray
photoelectron spectroscopy. The effects of polymer thickness on the electron transfer rates were
investigated. An immunosensor for selective detection of beta amyloid peptides Ab(1–42) was developed
via biofunctionalization of the pDAN modified SPGE with the anti-beta amyloid antibody used as the
peptide bioreceptor. The immunosensor has been used for specific detection of Ab(1–42) with a linear
range of 1 pg mL1 to 1000 pg mL1 and showed 1.4 pg mL1 and 4.25 pg mL1 detection and
quantification limit, respectively. The biosensor was further validated for the analysis of spiked human
plasma. The immunosensor enables rapid, accurate, precise, reproducible and highly sensitive detection
of Ab(1–42) using a low-cost SPGE platform, which opens the possibilities for diagnostic ex vivo
applications and research-based real time studies.1. Introduction
Alzheimer's Disease (AD) is the most common cause of
dementia that inuences millions of people across the world
and becomes more prevalent with aging. AD is a neurodegen-
erative disease triggered by extracellular accumulation of
amyloid b peptide (Ab), intracellular appearance of neuro-
brillary tangles and neuronal loss.1,2 This degeneration leads to
changes in behaviour, personality and functional capacity,
which deter the daily life of the patient. In 2020, an estimated 35
million people suffered from AD globally and it is predicted to
affect 115 million individuals by 2050.3 The existing investiga-
tion methods of AD are complicated and are usually made when
the disease is already in an advanced stage. In addition, there
are no treatments available to avoid this condition4 and currentring, Swansea University, Swansea, SA2
k; o.j.guy@swansea.ac.uk; Tel: +44 (0)
e, Swansea University, Swansea, SA2 8PP,
rche Farmacologiche Mario Negri IRCCS,
tion (ESI) available. See DOI:
the Royal Society of Chemistrytherapies only slow the advancement of the disease.4 Thus,
there is an intense need for the development of easy analytical
tools for the rapid detection of AD biomarkers for early-stage
point-of-care diagnosis.5–7 Ab(1–42) peptide is the key element
of the senile plaques present in AD.8 Other pathological char-
acteristics of AD consist of intraneuronal inclusions of hyper-
phosphorylated tau protein in neurobrillary tangles, together
with downstream processes such as inammation and oxidative
stress. Additionally, a certain isoform of apolipoprotein, ApoE4,
is the foremost genetic risk factor for AD, because it also leads to
excess of amyloid formation in the brain.9 All these components
cause the loss of synaptic integrity, progressive neuro-
degeneration and effective neural network connectivity.3,6,10
Ab(1–42) is usually expressed in cerebrospinal uid (CSF)
and plasma and it is found that the CSF levels of Ab(1–42) are
lower in AD patients than in normal controls, which indicates
amyloid pathology. Gagni et al. reported the detection of low
CSF Ab(1–42) levels at preclinical disease stages that predicted
future cognitive decline and neurodegeneration.11 An Ab(1–42)
concentration of <500 pg mL1 (0.1 nM) indicates that Ab(1–42)
is accumulating in the brain and not circulating in the CSF.11
However, more recently Emadi et al. reported that Ab(1–42)
concentration levels in peripheral blood serum samples at the


























































































View Article Onlineand 3.34  1.95 pg mL1 in young people.12 They stated that in
female AD patients with increasing age, more amounts of Ab(1–
42) remain in brain and thus appears less in the patient's
serum, whereas in male AD patients the amount of Ab(1–42)
that remains in the brain is smaller than that of Ab(1–40). It was
concluded that female AD patients would show more adverse
cognitive decline than male patients with increasing age
because the toxicity of Ab(1–42) has been shown to be far more
than that of Ab(1–40).12 It is therefore suggested that detection
of Ab(1–42) in physiological uids such as CSF, serum and
plasma at lower levels can be used for both screening of AD at
an early stage and for monitoring disease progression.
Several methods have been introduced to detect amyloid
beta using different sensing platforms.13–19 An enzyme linked
immunosorbent assay (ELISA), which is evaluated by western or
dot blot analysis, is currently used for its clinical detection.
Although these tests are reliable, they are labour intensive, time
consuming and require complicated instruments to perform
measurements. Also, the sensitivity of these tests is not
adequate to detect the ultra-low levels of the disease biomarkers
at the early stages of disease onset.
In 2013 Jeseung et al. reported a CNT lm-based biosensor
with a metal semiconductor eld effect transistor structure
(CNT-MESFET) for the real time detection of amyloid-b (Ab) in
human serum. Their sensor showed an LOD of 1 pg mL1
within the linear range of 1012 to 109 g mL1. Nevertheless,
the fabrication of this sensor is complex, costly and labour-
intensive.15
Electrochemical biosensors offer a rapid, cost-effective, easy
and sensitive testing technique.10,14,16,20,21 Furthermore, label-
free electrochemical immunosensors reduce sample
complexity because of the exclusion of potentially confounding
molecular labels.22,23 They provide a promising approach for
both sensitive and selective analysis due to their high compat-
ibility and repeatability, rapidness, simple instrumentation, low
power requirements and easy signal quantication.24–26 Label-
free sensors on the other hand can also be integrated into lab-
on-a-chip platforms and have the benet of using small
volumes for rapid and inexpensive measurements as opposed to
the label-based technologies which are oen more costly and
time-consuming.27 Pedro and co-workers used a modied gold
electrode surface for the sensitive detection of Ab(1–42). This
sensor showed good accuracy and reproducibility with a limit of
detection of 5.2 pg mL1. However, the selected antibody was
also able to recognize Ab(1–40), limiting the specicity of the
technique.16 Furthermore, Troung et al presented a label-free
impedimetric immunosensor using carbon disposable electro-
chemical printed chips modied with AuNPs, for the detection
of amyloid beta. They bound protein G to the antibody for its
controlled immobilization which in turn lowered the LOD to
0.57 nM.21
It has been reported that coating polymeric lms on the
electrode surface may well improve the behaviour and perfor-
mance of electrochemically modied electrodes.28,29 Further-
more, such modications may increase the reaction rate,
enhance the electrocatalytic properties of the substrates, and
the reproducibility and stability of the electrodes.30Nanoscale Adv.Poly(1,5diaminonaphthalene) (pDAN) is a conducting polymer
that is obtained from the polymerization of aromatic monomers
comprising of two amino groups.31 Thus, there are free amine
groups present in the polymer structure that aid in binding the
biomolecules to the electrode surface. The unique properties of
pDAN make it an outstanding material for electrochemical
electrode modication. Several studies have used pDAN in
electrochemical sensors for detection of, for example, H2O2,
cholesterol, H2O, dopamine and lactose.32–36
In this work we have used a graphene based electrode, due to
its high conductivity, large surface to volume ratio, low cost and
low environmental impact, in the fabrication of sensors and
biosensor-based devices.37,38 Graphene biosensors offer the
advantages of high sensitivity, lower detection limits and high
throughput detection when compared to other methods such as
ELISA, Polymerase Chain Reaction (PCR) and uorescence
assays. Myung-Sic et al. used oxygen-plasma-treated rGO
surfaces as reactive interfaces for the electrical detection of Ab
peptides, which in turn improved the antibody immobilization
on electrodes and yielded improved sensing performance due to
the enhancement in surface functionality. This was conrmed
by measuring the changes in the electrode's electrical charac-
teristics, with a 3.33-fold steeper slope for electrical responses
versus the analyte concentration curve of the oxygen plasma
treated sample compared to the untreated one.39 More recently
a graphene/rGO dual layer SPE was reported by Sethi and co-
workers for the detection of Ab(1–42). The proposed sensor
showed a detection limit of 2.398 pM with high selectivity.40
Here, we report the development of a label-free, electro-
chemical immunosensor, using graphene modied screen
printed electrodes (SPGEs) for high sensitivity detection of beta
amyloid peptides, isoform 42. The graphene surface was
modied with amine functional groups using a 1,5-dia-
minonaphthalene (DAN) electropolymerization process with
optimised amine surface coverage,41 whilst maintaining
minimal thickness for better charge transfer from the electro-
lyte solution to the electrode surface. Polymer DAN (pDAN)
modication provided controlled amount of amines without
even compromising the actual graphene properties. Subsequent
attachment of the anti-beta amyloid antibody on to the sensor
was performed and the inuence of antibody concentrations
with respect to Ab(1–42) peptide sensing efficiency has been
analysed in detail. BSA was used as the blocking agent. The
implications of this work towards developing a commercially
viable, robust and sensitive immunosensor for Alzheimer's
disease by using biomarker Ab(1–42) are presented.
2. Materials and methods
2.1. Materials
Graphene modied screen printed electrodes (SPGEs) were
purchased from Metrohm Ltd; 1,5-diaminonaphthalene (DAN)
(97%), 1-ethyl-3-(3-(dimethylamino)-propyl) carbodiimide
hydrochloride (EDC) (>98%), N-hydroxysuccinimide (NHS)
(98%), ferrocene carboxylic acid (FeCOOH) (97%), potassium
hexacyanoferrate(III) (>99%), potassium hexacyanoferrate(II)


























































































View Article Onlinetablets were supplied by Sigma-Aldrich and used as received.
Anti-beta amyloid antibody and beta-amyloid peptide (1–42)
human were obtained from Abcam Ltd.
2.2. Electropolymerization
Graphene electrode surfaces were functionalized with ultra-thin
polymer layers of 1,5-diaminonaphthalene (DAN) via an elec-
tropolymerization technique mentioned in detail in our
previous work.41 Typically, the polymer lms were deposited
from 10 mM DAN in 0.25 M H2SO4 using standard graphene
modied screen printed electrodes (SPGEs), where graphene
was used as the working electrode, carbon as the counter elec-
trode and Ag/AgCl as the reference electrode. Electro-
polymerization of the monomer DAN results in the deposition
of ultra-thin polymer DAN (pDAN) layers on the graphene
electrode surface, with the resulting pDAN layer containing NH2
functional groups which can subsequently be used for the
attachment of “bioreceptor” antibodies to the graphene surface.
Following pDAN deposition, the electrodes were rinsed with
deionized (DI) water and dried under nitrogen.
2.3. Bio-functionalization
Bio-functionalization protocols were optimised for improved
sensor performance. Typically, anti-beta amyloid antibody was
‘activated’ in a solution containing 5 mM EDC/NHS for 40
minutes. Once activated, the antibody solution was added to the
sensor surface and incubated for 30 minutes at 4 C. The anti-
body incubation time was optimised to achieve the highest
sensitivity for the proposed biosensor (Fig. S1†). The antibody
functionalised SPGE was then rinsed thoroughly with deionised
water, to wash away any non-specically bound probe on the
surface. Blocking of unbound NH2 surfaces was performed by
drop-casting 1% BSA onto the electrode surface and incubating
for 30 minutes at 4 C, subsequently removing any unbound
BSA by rinsing with DI water and drying with N2. In this work
0.1 mM concentration of PBS was used in all experiments in
order to increase the Debye length to approximately 7.3 nm and
hence to achieve better signal amplication.42
2.4. Amyloid beta (1–42) pre-treatment method
Ab(1–42) was received in the lyophilized form. It was rst dis-
solved in 10mM sodium hydroxide, followed by gentle vortexing
for less than 1 minute to make a homogeneous solution. It is
reported that under these highly alkaline conditions the peptide
is fully dissolved and exists only as monomers.43 The stock
solution was then aliquoted and stored at 20 C until further
use.
2.5. Human blood collection and plasma preparation
Human plasma samples were received from IRCCS – Istituto di
Ricerche Farmacologiche “Mario Negri” Via La Masa 19, 20 156
Milan – Italy. Fasting blood samples (3 mL) from AD patients
were collected by the venipuncture method. The aliquot was
centrifuged at 2000 rpm for 15 minutes at 4 C to separate the
plasma fraction. Aer that the plasma was transferred to a fresh© 2021 The Author(s). Published by the Royal Society of Chemistrytube, aliquoted and immediately frozen at 80 C till further
use. Informed consent was obtained from all human subjects.
Besides, all of the investigation protocols in this study have
been approved by relevant local ethics committee for clinical
research (Milan, Italy).2.6. Characterization
The electrode layers were characterized for their thickness using
Raman spectroscopy and X-ray photoelectron spectroscopy to
check the quality of the electrode.
X-ray photoelectron spectroscopic (XPS) measurements were
performed using a Kratos Axis Supra, with an Al Ka mono-
chromatic X-ray source, running at an emission current of 15
mA. Raman mapping measurements were performed using
a Renishaw system, with a 532 nm excitation laser and 2 mW
power, before and aer pDAN modication on the electrode
surface.
Electrochemical analysis was done using an advanced
potentiostat (PGSTAT-302N, Metrohm AutoLab, Runcorn, UK).
Square wave voltammetry (SWV) and differential pulse voltam-
metry (DPV) were used as characterization techniques with the
scanning voltage in the range of 0.2 V to 0.5 V for evaluating
the electrochemical performance of blank and modied elec-
trodes. 5 mM K3[Fe(CN)6]/K4[Fe(CN)6] in 0.1 mM PBS solution
(pH ¼ 7.4) was used as an electrolyte.3. Results and discussion
3.1. Graing pDAN layers on SPGEs
To enable biofunctionalization, SPGE surfaces were modied
with poly-1,5-diamino naphthalene (pDAN) layers using elec-
tropolymerization as described in Section 2.2. Fig. S2† shows
the voltammetric response of SPGEs during the electro-
polymerization process. The dominant peak at 0.55 V (vs. Ag/
AgCl) corresponds to the oxidation of the monomer DAN
species, which reduces subsequently with increase in the
number of scan cycles, indicating that DAN monomers are
being oxidised and converted into polymers. Also, a new peak at
0.3 V originating during the second cycle is attributed to poly-
mer layer formation and this peak increases with increase in the
scan cycles. Polymer layer thickness was controlled via
controlling the number of scan cycles. In order to achieve
a greater number of surface amine groups for bio-
functionalization, SPGE electrodes were modied with pDAN
layers of different thicknesses.413.2. Mechanism of action of pDAN/graphene interfaces
3.2.1. Electrochemical analysis. The electroactivity of the
deposited pDAN lms was studied using cyclic voltammetry.
Fig. S3† shows cyclic voltammetry curves of pDAN layers in
5 mM Fe2+/Fe3+ redox couple at the scan rates of 10–100 mV s1
(discussed in detail in Section 3). To further analyze these
systems, the charge transfer diffusion coefficient, DCT, was
calculated using the Randles–Sevcik equation (eqn (1)):


























































































View Article Onlinewhere Ip represents the peak current, A is the area of the elec-
trode (0.1256 cm2), n is the number of electrons transferred (n¼
1), C is the concentration of the redox species (5 mM), D is the
charge transfer diffusion coefficient (DCT) and y is the scan rate.
The blank graphene electrode displayed a typical DCT of 13.2 
106 cm2 s1 due to its high electronic mobility. The charge
transfer diffusion coefficient was highest (6.80  106 cm2 s1)
during the rst cycle of pDAN deposition, which was as ex-
pected, as the single layer of monomer DAN (Fig. S5†) allows the
most facile charge transfer to the graphene surface. With
increase in pDAN layer thickness to 2 cycles DCT decreases to
4.88  106 cm2 s1 and again increases at its maximum (5.87 
106 cm2 s1) at 3 cycles indicating that a uniform pDAN
monolayer is achieved, followed by a decrease again to 3.29 
106 cm2 s1 and 1.03  106 cm2 s1 at 5 and 10 cycles, respec-
tively. This shows that the electron transfer rates are affected by
the thickness of the pDAN layer and thus, the pDAN layer
should be optimized in terms of maximizing the number of
surface NH2 groups, whilst maintaining the highest possible
electron transfer rates.
3.2.2. Quantication of amine surface groups. The effi-
ciency of chemical functionalization was analyzed by estimating
the number of surface amine groups upon pDAN modication
via functionalizing the DAN-modied electrodes with ferrocene
carboxylic acid (FCA), using a standard EDC/NHS coupling
reaction. Fig. 1a shows the cyclic voltammogram of FCA func-
tionalized graphene and pDAN modied SPGEs. The electrodes
were scanned between 0.2 V and 0.3 V at 5 mV s1 scan rate.
No redox peak is found for blank SPGE upon FCA functionali-
zation due to the lack of amine functional groups present on the
surface, whereas at 0.07 V and 0.04 V strong redox peaks are
observed for FCA functionalized pDAN modied SPGEs, which
correlate with the oxidation and reduction of the ferrocene
moiety, respectively. The ferrocene surface coverage was esti-
mated using eqn (2):
G ¼ Q/nFA (2)
where Q is the charge obtained by integrating the anodic peak at
a low scan rate (coulomb), n is the number of electrons trans-
ferred, F is the Faraday constant (96 485 s A mol1) and A is the
geometrical area of the electrode (0.1256 cm2). Fig. 1b shows the
surface coverage dependence on the number of scan cycles. AsFig. 1 (a) Cyclic voltammogram of ferrocene carboxylic acid func-
tionalized SPGE and pDAN modified SPGEs at different scan cycles.
PBS was used as the electrolyte and the CVs were recorded at a 5 mV
s1 scan rate. (b) Bar chart showing amine surface coverage vs. the
number of pDAN scan cycles.
Nanoscale Adv.anticipated, it is found that the amine surface coverage
increases with increase in pDAN layer thickness (scan cycles),
which is also attested by the increase in the capacitive current.
Although the higher pDAN layer thickness produces large
amine density on the surface, it is found that the charge transfer
characteristics decrease aer reaching a certain thickness
(Section 3.2.1). Thus, it is critical to nd a fair balance between
increased amine surface coverage as well as charge transfer
characteristics. For our experiments – 3 cycles of pDAN layers (3-
pDAN) were chosen to be the optimal layer thickness for further
electrochemical sensor development.
3.2.3. Structural and chemical analysis. Raman spectro-
scopic analyses of pristine SPGEs and pDAN-modied SPGEs are
shown in Fig. 2a. The Raman spectrum of pristine SPGE is similar to
that of pristine graphene, showing the D, G and 2D band positions at
1350 cm1, 1580 cm1 and 2700 cm1 respectively.44 The corre-
sponding intensity ratio obtained from G and 2D bands of the pris-
tine SPGEs was 0.46633, which conrms the presence of the few layer
graphene structure on the screen-printed electrode. Aer pDAN
modication, the intensity ratio of G and 2D bands of the pDAN
modied SPGE was found to be 0.42407. The intensity ratios of the D
and G bands of the pristine and pDAN modied SPGEs were calcu-
lated to be 0.46633 and 0.42407, respectively. Taking device variation
into consideration, no signicant variations were found in the
intensity and position of the D, G and 2D bands upon pDAN modi-
cation, alluding that very little structural deformation is induced to
the graphene upon electropolymerization.
X-ray photoelectron spectroscopy is a tool used to investigate
the chemical environment of graphene modied with foreign
dopants.41,45 To study the inuence of electropolymerization on
SPGEs, XPS measurements were carried out on blank and pDAN
modied SPGE surfaces. Fig. 2b–d show XPS graphs of the wide
spectrum (b), N 1s spectrum (c) and C 1s spectrum (d) of pris-
tine graphene and pDAN modied SPGEs. The wide scan
acquisition of pristine and pDANmodied SPGE shows a typical
C 1s peak at 284 eV. Unlike pristine graphene, the pDAN
modied SPGE shows a clear peak at 400 eV in the wide
spectra (Fig. 2b), conrming that nitrogen-based moieties were
introduced aer electropolymerization. The atomic concentra-
tions of C, O and N present were calculated from the XPS spectra
and are listed in Table S2.† It is found that the atomic
percentage of N increases drastically upon electro-
polymerization and additional components appear in the C
spectra (Fig. 2d), which can be ascribed to the carbon and
nitrogen species present in DAN. To further analyse the nature
of C, O, and N species, the N 1s (Fig. 2c) and C 1s (Fig. 2d) peaks
were tted with Gaussian/Lorentzian peaks to analyse the
distribution of carbon and nitrogen bonding. The C 1s peak of
pDAN modied graphene was deconvoluted into six carbon
peaks, which are ascribed to Caromatic (284.04 eV), Caliphatic
(284.56 eV), C–N (285.44 eV), C–O (286.14), C]O/C]N
(287.20 eV) and O–C]O/N–C]O (288.76 eV). The N 1s peak
of pDANmodied graphene is observed at 400.16 eV, indicating
that nitrogen compounds are present upon successful electro-
polymerization. Furthermore, the three tted peaks at
400.12 eV, 402.26 eV and 403.59 eV correspond to C–N, C–
NH and N–H groups respectively, conrming that the pDAN© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 2 Comparison of blank and pDAN functionalized graphene SPE at 3 scan cycles (a) Raman spectrum; (b) XPS spectrum showing wide scan,


























































































View Article Onlineelectropolymerization process generates –NH2 groups on the
graphene surface.463.3. Mechanism of antibody/pDAN/graphene interfaces
3.3.1. Electrochemical analysis. A carboxyl terminated anti-
beta amyloid antibody specic to Ab(1–42) peptide was immo-
bilized onto the pDAN modied SPGE surface via carbodiimideFig. 3 (a) Schematic representation of the electrochemical immunosens
(b) differential pulse voltammetry (DPV) response; (c) square wave voltam
© 2021 The Author(s). Published by the Royal Society of Chemistrylinkage using an EDC/NHS protocol.47 Fig. 3 (a) shows the
schematic representation of the sensor while (b) shows the
differential pulse voltammetric (DPV) response and (c) the
square wave voltammetric (SWV) response of SPGE at each stage
of functionalization. An increase in the peak current is observed
upon pDAN functionalization, which could be attributed to the




























































































View Article Onlinedue to the high conductivity of the amine (NH2) layer.48 Slight
peak broadening is also observed which may be due to the non-
uniform coating of pDAN layers. The subsequent antibody
functionalization reduces the available sites for charge transfer
via blocking, and thus a drastic reduction in the peak current is
observed. This shows that the antibody functionalization
impedes the charge transfer process at the electrode/electrolyte
interface. Similarly, blocking of unbound NH2 sites at the
electrode surface using BSA further reduces the peak current,
suggesting the successful biofunctionalization of pDAN modi-
ed SPGEs with antibody and BSA.
3.3.2. Optimising the antibody concentrations. The
concentration of the biomolecules immobilised onto the elec-
trode surface greatly inuences the immunosensor perfor-
mance. Thus, optimising the antibody concentration is critical
to ensure the superior performance of the electrochemical
immunosensor. In this work, we have investigated the inuence
of the immobilised antibody concentrations on sensing. A
controlled immobilization of anti-beta amyloid antibody onto
pDAN modied SPGEs was achieved by varying the antibody
concentrations (20, 40 and 60 mg mL1). Electrochemical anal-
ysis of the antibody attached SPGEs was performed using DPV
and SWV, respectively. It is observed that the peak current
produced via the electron transfer upon the [Fe(CN)6]3/4
redox process is greatly inuenced by the amount of antibody
immobilised onto the electrode surface. Fig. 4a shows the
dependence of the percentage of peak current reduction on the
concentration of the antibodies. It is evident that 60 mg mL1 Ab
antibodies reduce the current by 25% whereas 40 mg mL1
antibodies reduce the current by 20% and a much lower level
of peak current reduction by14% is observed with 20 mg mL1
anti-beta amyloid antibodies. This could be clearly attributed to
the increased antibody surface coverage at the electrode which
could increase the steric barrier for the [Fe(CN)6]3/4 redox
system in accessing the electrode surface – resulting in
decreased peak current generation.Fig. 4 (a) Peak current reduction in DPV and SWV measurements (%ir) a
current on exposure to DI water and PBS (0.1 mM) (n ¼ 3).
Nanoscale Adv.3.3.3. Optimising the sensor for false-positives. Analysis of
the effect of sensor response to false positives, i.e., to PBS and DI
water was performed by considering the effect of 0.1 mM PBS
and DI water exposure on the sensors (antibody functionalized
SPGEs). Exposure to PBS and DI water was repeated multiple
times. Fig. 4b shows the percentage change in the peak current
upon exposing the sensors to 0.1 mM PBS and DI water. A
considerable change (7–8%) in the peak current is observed
upon exposure to 0.1 mM PBS. A similar effect is observed for DI
water exposure, which could be ascribed to the high sensitivity
of the graphene-based electrode surface. The relative current
change corresponding to 0.1 mM PBS and beta amyloid
peptides Ab(1–42) binding to the antibody/BSA-bound surface
was estimated using eqn (3):49




where ibaseline and iantibody/BSA/antigen or PBS are the mean DPV
currents obtained at unmodied (blank) and antibody/BSA/
Ab(1–42) antigen or PBS modied electrodes, respectively. It is
found that antibody functionalised electrodes show signicant
change in the peak current with exposure to the relative peptide
compared to changes observed on exposure to 0.1 mM PBS only
(Fig. 5). The repeated exposure of antibody functionalised
SPGEs to 0.1 mM PBS only showed reproducible changes in
current. However, the current change was minimal (1–1.5%)
when compared to the change measured upon peptide binding.
Thus, to moderate the effect of PBS, every sensor was exposed to
0.1 mM PBS rst before performing the actual peptide sensing
measurement in order to saturate the electrode surface with
PBS.
3.4. Evaluating the electrochemical immunosensor
performance
3.4.1. Sensitivity analysis. The electrochemical immuno-
sensor performance was evaluated by exposing the antibodyt each concentration of Ab antibody. (b) Percentage reduction in peak
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 5 Bar chart illustrating the peak current reduction (%ir) with exposure to 0.1 mM PBS only (negative runs with respect to each peptide


























































































View Article Onlinefunctionalised electrodes to different concentrations of beta
amyloid peptides Ab(1–42) ranging from 1 pg mL1 to 2 mg
mL1 at 4 C, each for incubation times of 20 minutes. This was
expected to result in the successful binding of the beta amyloidFig. 6 Differential pulse voltammetry (DPV) results at 20 mgmL1, 40 mgm
20 mg mL1, 40 mg mL1 and 60 mg mL1 antibodies at each stage of sens
concentrations. All data points are mean values of three independent el
a measure of repeatability of the system (n ¼ 3).
© 2021 The Author(s). Published by the Royal Society of Chemistrypeptides Ab(1–42) to the anti-beta amyloid antibodies, which
would in turn affect the [Fe(CN)6]3/4 electron transfer. It is
found that the peak current decreased signicantly with an
increase in the peptide concentration from 1 pg mL1 to 2 mgL1 and 60 mgmL1 concentration of Ab antibodies: (a–c) DPV plots of
ing; (d–f) corresponding calibration curves of Ip as against log Ab(1–42)
ectrodes. The error bars (calculated as the standard deviation) provide
Nanoscale Adv.
Table 1 An overview of recently reported label-free biosensors for Ab(1–42) detectiona












Graphene/rGO SPE Anti Ab(1–42) antibody (H31L21)/Pyr-NHS/graphene-rGO SPE DPV 10.8* 40
Si/SiO2 (Range of antibodies**)/poly(DMA-co-NAS-co-MAPS)/silicon
microarrays
Fluorescence 73 11
Carbon ink electrode of DEP
chip
Monoclonal Ab antibody/protein G/MHDA SAM/AuNPs/carbon
DEP chip
EIS 2573.02* 21
ICE-Au Anti-Ab antibody (MOAB-2)/EDC-NHS/MHA SAM/ICE EIS 70, 100 51
Graphene SPE Anti Ab(1–42) antibody (mOC64)/pDAN/graphene SPE DPV 1.4 This
work
a *Values were converted from pM and nM to pg mL1. **SC-D17, NT-11H3, NT-8G7, Cov-4G8 and Cov-12F4.
Fig. 7 Peak current reduction %ir obtained from DPV and SWV plots
for non-specific testing using APO-E4, Ab(1–40), Tau-352 and Ab(1–


























































































View Article OnlinemL1. This is because increasing the concentration leads to
high accumulation of proteins on the electrode that in turn
blocks the [Fe(CN)6]3/4 redox system from accessing the
electrode surface. Saturation of the electrode surface is
observed at >1000 pg mL1 peptide concentrations with 20 mg
mL1 antibody electrode. Fig. 6 shows the sensor performance
and calibration curve of peak current variation vs. log of
concentration of the beta amyloid peptides for SPGEs modied
with antibody Ab(1–42) concentrations of 20, 40, and 60 mg
mL1, respectively. The calibration curve shows a linear rela-
tionship between the peak current and log[peptide concentra-
tion]. Our electrochemical sensor showed a wide linear
response between 1 pg mL1 and 1000 pg mL1 (Fig. 6d–f).
The limit of detection (LOD) and limit of quantitation (LOQ)
for the precise detection of amyloid b peptide (1–42) were
calculated within the linear range of 1 pg mL1 to 1000 pg
mL1, utilising the standard deviation of the intercepts and the
average of slopes of the straight lines from the analytical curves,
using the following equations:16,40,52,53
LOD ¼ 3.3(SD of the lowest concentration/SLOPE) (4)
LOQ ¼ 10(SD of the lowest concentration/SLOPE) (5)
where SD is the standard deviation of the predicted peak
current values, and SLOPE is the slope of the calibration line.
Table S3† shows the list of LODs and LOQs obtained for the
electrodes functionalised with different concentrations of
antibody. Sensors functionalised with 20 mg mL1 antibody
show the lowest LOD, 1.4 pg mL1 and 4.25 pg mL1 LOQ. It is
observed that the LOD increased with increase in the concen-
tration of the surface bound antibodies, indicating the signi-
cance of achieving an optimal antibody loading onto the sensor
surface. Our sensor shows higher sensitivity over the other
existing label-free biosensors (Table 1).
3.4.2. Specicity and stability analysis. To test the selec-
tivity and specicity of our sensors for Ab(1–42) detection, the
antibody immobilised sensors were incubated with 1000 pg
mL1 concentrations of APO-E4, Ab(1–40), Tau-352 and Ab(1–
42) proteins, respectively. Fig. 7 shows the percentage change inNanoscale Adv.the peak current (DPV measurements) upon binding with APO-
E4, Ab(1–40), Tau-352 and Ab(1–42). A very small change (2–
4.5%) in peak current is observed for APO-E4, Ab(1–40) and Tau-
352 proteins compared to Ab(1–42) protein (16–21% change).
The small changes on exposure to non-specic proteins may be
because of graphene's sensitivity towards PBS (as discussed in
Section 3.3.3.) and some non-specic adsorption of the peptides
onto the sensors. In contrast, a very strong change is observed
aer addition of Ab(1–42) peptide due to the formulation of the
antibody–antigen complex. These data conrm the selectivity of
the fabricated sensor to the Ab(1–42) peptides.
The stability of the immunosensor was also examined by
storing the antibody modied SPGEs in a refrigerator at 4 C for
1 week. The current response of the prepared immunosensor
decreased by 22% aer eight days, thus representing an
acceptable stability.
3.4.3. Spiked plasma analysis. Blood-based detection of
Alzheimer's biomarkers is emerging as a promising alternative
to the traditional strategies.54 In this study human plasma was© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 8 (a) DPV response from spiked concentrations of Ab(1–42) (at 1, 10, 100 and 1000 pg mL1) in human plasma. (b) Bar chart illustrating the
comparison of peak current reduction (%ir) with exposure to the different concentrations of Ab(1–42) spiked in human plasma and 0.1 mM PBS


























































































View Article Onlinerst diluted with PBS in the ratio 10 : 100 and later spiked with
known concentrations of beta amyloid peptide Ab(1–42)
including 1, 10, 100 and 1000 pg mL1 respectively. The
percentage reduction in peak current (%ir) vs. log of peptide
concentrations (pg mL1) is shown in Fig. 8. The peak current
reduction (%ir) with exposure to the 0.1 mM PBS was also
replotted here to show a comparison with the human plasma
results. A signicant reduction of DPV signal (up to 27%) in
spiked samples was observed as compared to the PBS only
samples (up to 9.8%). These results validate the applicability of
the proposed method in clinical sample analysis.4. Conclusions
In summary, a simple and rapid label-free electrochemical
biosensor, based on a modied graphene screen printed elec-
trode, has been developed for highly sensitive and selective
detection of Ab(1–42). Under the optimized conditions, our
proposed immunosensor exhibited excellent analytical perfor-
mance for Ab(1–42) with a wide linear range and low detection
limit. Antibodies targeted against Ab(1–42) were immobilised
onto the amine surface using EDC/NHS chemistry to obtain
preferential antibody orientation attachment. Furthermore,
three different concentrations of anti-beta amyloid antibody
were used in order to understand the effects that each
concentration had on Ab(1–42) detection sensitivity. The sensor
showed negligible response to the non-specic interactions
with Tau-352, Ab(1–40) and APO-E4 proteins. It also showed
excellent sensing performance for spiked human plasma
samples. Our proposed immunosensor modication method
can certainly be used for the detection of other proteins, with
optimisation of detection platforms enabling tuning of the
sensitivity range. With all these characteristics, the main limi-
tation of our biosensor is its sensitivity towards the water and
PBS only samples. Therefore, for future work we are aiming to© 2021 The Author(s). Published by the Royal Society of Chemistrydevelop a biosensor with negligible sensitivity towards these
uids.
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